https://www.frontiersin.org/articles/10.3389/fnsyn.2018.00018/full?
- 1Ottawa Hospital Research Institute (Neuroscience Program), Ottawa, ON, Canada
- 2University of Ottawa Brain and Mind Institute, Ottawa, ON, Canada
- 3Departments of Medicine, Cellular and Molecular Medicine, and Psychiatry, University of Ottawa, Ottawa, ON, Canada
Introduction
Stroke refers to an interruption of blood supply to some
regions of the brain. This can be either ischemic (about 85% of strokes)
or hemorrhagic (about 15% of strokes) (Auriat and Colbourne, 2008).
Stroke is a major cause of disability in adults. In 2008 stroke was the
cause of 5.7 million deaths and 46.6 disability-adjusted life years
worldwide (Oczkowski, 2013).
Stroke survivors are left with damage to their brain resulting in
various impaired domains of function. Among the most common of these is
motor deficits, affecting up to 80% of patients (Langhorne et al., 2009).
Currently available interventions for stroke include clot-busting
approaches such as thrombolytic drugs or angioplasty. These
interventions are only available in select cases and only in the
hyperacute stage of stroke. Once the patient has stabilized, a
combination of spontaneous recovery and rehabilitation allow them to
regain some function. While rehabilitation methods such as physical
therapy have been shown to be more useful than no rehabilitation at all,
no one physiotherapy treatment has been shown to be more efficacious
than the others (Oczkowski, 2013).
Additionally, physical rehabilitation is only available to individuals
who are well enough to complete it. Unfortunately, with currently
available treatments, 40–60% of stroke patients still present with motor
deficits in the chronic stage, after recovery has plateaued (Acler and Manganotti, 2013).
There is a need for more strategies to enhance stroke recovery. One
approach, pharmacotherapy, uses drugs and physical rehabilitation to
boost recovery. Several classes of drugs have been investigated for this
purpose, including selective serotonin reuptake inhibitors (SSRIs),
cholinergic agents and dopamine (DA)-enhancing drugs (Rösser and Flöel, 2008; Viale et al., 2018).
However, none of these therapies have been approved for routine
clinical use in stroke recovery. Herein, we argue that interventions
targeting the dopaminergic system hold particular promise. Indeed,
stroke impacts the dopaminergic system, and this combined with the
normal decline in DA function and motor learning abilities with age,
makes it a relevant target. There is robust evidence in animal stroke
models showing that DA-enhancing drugs can improve motor recovery,
through a myriad of potential mechanisms that remain to be fully
understood. Lastly, clinical investigations suggest that this may be a
valid therapeutic tool for stroke survivors, although better selection
of patient groups may be required. This review will focus on
interactions between the dopaminergic system and the poststroke brain,
specifically as it pertains to motor recovery. To this end, we have
excluded evidence relating to therapeutic targeting of dopaminergic
system in the facilitation of recovery from traumatic brain injury.
More at link.
No comments:
Post a Comment